Core Viewpoint - A class action securities lawsuit has been filed against Firefly Aerospace Inc. due to alleged securities fraud affecting investors who purchased shares during the company's IPO and subsequent period [1][2]. Group 1: Lawsuit Details - The lawsuit aims to recover losses for investors who acquired Firefly common stock during its IPO on August 7, 2025, and securities between August 7, 2025, and September 29, 2025 [2]. - The complaint alleges that Firefly overstated demand and growth prospects for its Spacecraft Solutions offerings and the operational readiness of its Alpha rocket program, which could have a material negative impact on the company [3]. Group 2: Next Steps for Investors - Investors who suffered losses during the relevant time frame have until January 12, 2026, to request to be appointed as lead plaintiff, although participation in any recovery does not require serving as lead plaintiff [4]. - Class members may be entitled to compensation without any out-of-pocket costs or fees [4]. Group 3: Legal Representation - Levi & Korsinsky, LLP has a strong track record in securities litigation, having secured hundreds of millions of dollars for shareholders over the past 20 years [5].

Core Viewpoint - A class action securities lawsuit has been filed against Telix Pharmaceuticals Ltd. due to alleged securities fraud affecting investors between February 21, 2025, and August 28, 2025 [1][2]. Group 1: Lawsuit Details - The lawsuit claims that the defendants made false statements and concealed information regarding Telix's progress in prostate cancer therapeutic candidates, the quality of its supply chain, and the overall business prospects of the company [3]. - Investors who suffered losses during the specified timeframe have until January 9, 2026, to request to be appointed as lead plaintiff, although participation does not require serving in this role [4]. Group 2: Legal Representation - Levi & Korsinsky, LLP has a strong track record in securities litigation, having secured hundreds of millions of dollars for shareholders over the past 20 years and consistently ranking among the top securities litigation firms in the United States [5].

Core Viewpoint - Inspire Medical Systems, Inc. is facing a class action lawsuit due to alleged securities fraud related to the poor launch of its new product, Inspire V, which was marked by significant operational failures and misrepresentations to investors [3]. Group 1: Lawsuit Details - The lawsuit aims to recover losses for investors affected by alleged securities fraud between August 6, 2024, and August 4, 2025 [2]. - Defendants are accused of making false statements and concealing the poor demand for Inspire V, as providers had excess inventory and were hesitant to adopt the new treatment [3]. - Key operational failures included incomplete training for treatment center customers, lack of necessary IT systems, and failure to secure Medicare reimbursement prior to the product launch [3]. Group 2: Next Steps for Investors - Investors who suffered losses during the specified timeframe have until January 5, 2026, to request appointment as lead plaintiff, although participation does not require this role [4]. - Class members may be entitled to compensation without any out-of-pocket costs or fees [4]. Group 3: Legal Representation - Levi & Korsinsky, LLP has a strong track record in securities litigation, having secured hundreds of millions for shareholders over the past 20 years [5]. - The firm is recognized as one of the top securities litigation firms in the United States, with extensive expertise in complex cases [5].

Accessibility StatementSkip Navigation NEW YORK, Nov. 25, 2025 /PRNewswire/ -- Levi & Korsinsky, LLP notifies investors in Freeport- McMoRan Inc. ("Freeport-McMoRan Inc." or the "Company") (NYSE: FCX) of a class action securities lawsuit. CLASS DEFINITION: The lawsuit seeks to recover losses on behalf of Freeport-McMoRan Inc. investors who were adversely affected by alleged securities fraud between February 15, 2022 and September 24, 2025. Follow the link below to get more information and be contacted by a ...

Core Viewpoint - A class action lawsuit has been filed against CarMax, Inc. and certain senior executives for securities fraud following a significant stock drop attributed to potential violations of federal securities laws [1][2]. Group 1: Lawsuit Details - Investors have until January 2, 2026, to request to lead the case, which is pending in the U.S. District Court for the District of Maryland [2]. - The lawsuit asserts claims under Sections 10(b) and 20(a) of the Securities Exchange Act of 1934 on behalf of CarMax investors [2]. Group 2: Company Performance and Stock Impact - CarMax reported disappointing financial results for Q2 of fiscal year 2026, including a 5.4% decline in retail used unit sales, a 6.3% decline in comparable store used unit sales, and a 2.2% decline in wholesale units [5]. - The company's net income for Q2 was approximately $95.4 million, down from $132.8 million the previous year, attributed to a "pull forward" in demand due to U.S. tariffs [5]. - Following the financial report, CarMax's stock dropped $11.45 per share, or roughly 20%, from $57.05 on September 24, 2025, to $45.60 on September 25, 2025 [6]. - An unexpected departure of CEO Bill Nash on November 6, 2025, and a weak preliminary Q3 2025 outlook led to an additional stock drop of over 24% [6]. Group 3: Company Background - CarMax is a leading retailer of used cars, emphasizing a strong customer experience and sustainable demand [3]. - The firm Bleichmar Fonti & Auld LLP, known for representing plaintiffs in securities class actions, is handling the lawsuit against CarMax [10].

Core Viewpoint - A class action lawsuit has been filed against Telix Pharmaceuticals Ltd. for allegedly making false or misleading statements regarding its business operations and prospects during the specified class period [1][3]. Group 1: Lawsuit Details - The lawsuit is on behalf of investors who purchased Telix securities from February 21, 2025, to August 28, 2025 [1][2]. - Investors have until January 9, 2026, to seek appointment as lead plaintiff representatives [2]. Group 2: Allegations Against the Company - Defendants are accused of overstating progress on prostate cancer therapeutic candidates [3]. - The quality and performance of the Company's supply chain and partners were allegedly exaggerated [3]. - As a result of these misrepresentations, statements regarding the Company's business and operations were claimed to be false or misleading [3]. Group 3: Company Background - Telix Pharmaceuticals is a biopharmaceutical company based in Melbourne, Australia, focusing on radiopharmaceutical development for cancer treatment [2].

Core Viewpoint - A class action lawsuit has been filed against Synopsys, Inc. and certain senior executives for securities fraud following a significant stock drop due to potential violations of federal securities laws [1]. Group 1: Lawsuit Details - The lawsuit is pending in the U.S. District Court for the Northern District of California, captioned Kim v. Synopsys, Inc., et al., No. 3:25-cv-09410 [3]. - Investors have until December 30, 2025, to request to be appointed to lead the case [3]. Group 2: Company Performance - Synopsys provides design automation software products, with its Design IP segment being the fastest-growing, increasing from 25% of revenue in 2022 to 31% in 2024 [4]. - The company reported Q3 2025 results showing a revenue decline in the Design IP segment to $425.9 million, a 7.7% decrease year-over-year, and a net income of $242.5 million, down 43% year-over-year [6]. Group 3: Market Reaction - Following the release of disappointing Q3 results, Synopsys stock fell nearly 36%, from $604.37 per share on September 9, 2025, to $387.78 per share on September 10, 2025 [6].

Core Viewpoint - A class action lawsuit has been filed against Stride, Inc. for securities fraud, following significant stock drops attributed to potential violations of federal securities laws [1][2]. Company Overview - Stride, Inc. is an education technology company that provides an online platform for students across the U.S. [3]. Allegations - The lawsuit claims that Stride inflated enrollment numbers by retaining "ghost students," failed to comply with employee background checks and licensure laws, and provided a poor customer experience leading to higher withdrawal rates and lower conversion rates [3][4]. Stock Performance - On September 14, 2025, Stride's stock dropped by $18.60 (over 11%) from $158.36 to $139.76 per share following the fraud allegations [4]. - On October 28, 2025, Stride admitted to issues with customer experience, resulting in an estimated 10,000-15,000 fewer enrollments, causing the stock to plummet by $83.48 (over 54%) from $153.53 to $70.05 per share [5]. Legal Proceedings - Investors have until January 12, 2026, to request to lead the case in the U.S. District Court for the Eastern District of Virginia [2].

Core Viewpoint - A class action lawsuit has been filed against Inspire Medical Systems, Inc. and certain senior executives for securities fraud following a significant stock drop due to potential violations of federal securities laws [1][3]. Company Overview - Inspire Medical Systems develops and manufactures an implantable medical device for the treatment of sleep apnea, with the latest version being Inspire V, which received FDA approval on August 2, 2024 [4]. Allegations and Issues - The lawsuit claims that Inspire misled investors by assuring them that all necessary steps were taken for the launch of Inspire V, while in reality, the company failed to prepare clinicians and payors adequately, leading to significant delays in adoption [5][6]. - The launch of Inspire V faced weak demand as many customers had excess inventory of older devices, which contributed to the poor market reception [6]. Stock Performance - On August 4, 2025, Inspire disclosed that the launch of Inspire V would take longer than expected, resulting in a reduction of its 2025 earnings per share guidance by over 80% [7]. - Following this announcement, Inspire's stock price dropped by $42.04 per share, or more than 32%, from $129.95 on August 4, 2025, to $87.91 on August 5, 2025 [8].

Core Viewpoint - A class action lawsuit has been filed against Freeport-McMoRan Inc. and certain senior executives for securities fraud, following significant stock drops attributed to potential violations of federal securities laws [1][3]. Group 1: Lawsuit Details - The lawsuit is pending in the U.S. District Court for the District of Arizona, captioned Reed v. Freeport-McMoRan Inc., et al., No. 2:25-cv-04243 [3]. - Investors have until January 12, 2026, to request to be appointed to lead the case [3]. Group 2: Company Operations and Safety Claims - Freeport-McMoRan operates the Grasberg Copper and Gold Mine in Indonesia, where it has been accused of overstating its commitment to safety while conducting unsafe mining practices [4][5]. - The company had previously promoted its safety procedures, including the use of data and technology to prevent fatal incidents [4]. Group 3: Stock Price Impact - On September 9, 2025, Freeport's stock dropped by $2.77 per share (over 5.9%) following a press release about suspended mining operations due to a landslide [6]. - Following an update on September 24, 2025, indicating two fatalities and a projected 4% and 6% decrease in copper and gold sales, the stock fell by $7.69 per share (almost 17%) [7]. - On September 25, 2025, reports of strained relations with the Indonesian government led to an additional drop of $2.33 per share (over 6%) [8]. - An Indonesian news report on September 28, 2025, suggested the incident was preventable, further impacting investor confidence [9].